Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes

Drug Testing and Analysis

Volumn 6, Issue 11-12, 2014, Pages 1102-1107

  Görgens, Christian ^a   Guddat, Sven ^a   Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Doping; High resolution high accuracy MS; HILIC; Human urine; ITPP; Orbitrap; Sports drug testing

Indexed keywords

ALCOHOLS; BODY FLUIDS; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DRUG PRODUCTS; HYDROPHILICITY; MASS SPECTROMETRY; OXYGEN; POLYOLS; SUGARS;

DOPING CONTROL; DRUG TESTING; HIGH RESOLUTION; HIGH RESOLUTION/HIGH ACCURACY MS; HIGH-ACCURACY; HUMAN URINE; HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHIES; INOSITOL TRISPYROPHOSPHATE; ORBITRAP; SPORT DRUG TESTING;

CELL MEMBRANES;

EFAPROXIRAL; HEMOGLOBIN; INOSITOL DERIVATIVE; MYO INOSITOL TRISPYROPHOSPHATE; PYROPHOSPHORIC ACID DERIVATIVE; UNCLASSIFIED DRUG; INOSITOL PHOSPHATE; INOSITOL TRISPYROPHOSPHATE; PERFORMANCE ENHANCING SUBSTANCE;

ACCURACY; ANALYTIC METHOD; ARTICLE; ATHLETE; DOPING; EXERCISE; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; HYDROPHILICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RELIABILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SCREENING TEST; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION STUDY; CHEMICAL PHENOMENA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES; REPRODUCIBILITY; URINE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPING IN SPORTS; HEMOGLOBINS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INOSITOL PHOSPHATES; PERFORMANCE-ENHANCING SUBSTANCES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84923251160     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1700     Document Type: Article

References (29)

1. WADA. The 2014 Prohibited List International Standard. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2014/WADA-prohibited-list-2014-EN.pdf [12 March 2014].
2. M. Perutz Stereochemistry of cooperative effects in haemoglobin. Nature 1970, 288, 726.
3. J. F. Gibson, D. J. Ingram, M. F. Perutz Orientation of the four haem groups in haemoglobin. Nature 1956, 178, 906.
4. R. Benesch, R. B. Benesch Intracellular organic phosphates as regulators of oxygen release by haemoglobin. Nature 1969, 221, 618.
5. H. K. Eltzschig, P. Carmeliet Hypoxia and Inflammation. New Engl. J. Med. 2011, 364, S656.
6. M. Gassman Hypoxia, from integrative biology to human disease. High Alt. Med. Biol. 2008, 9, 100.
7. J. Suth Efaproxiral: A novel radiation sensitiser. Expert Opin. Inv. Drug 2004, 13, 543.
8. A. Breidbach, D. H. Catlin RSR13, a potential athletic performance enhancement agent: Detection in urine by gas chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2001, 15, 2379.
9. C. Jimenez, R. Ventura, J. Segura Detection in urine of efaproxiral (RSR13), a potential doping agent, by a routine screening procedure based on methylation followed by gas chromatography/mass spectrometry. Anal. Chim. Acta 2004, 505, 227.
10. M. Thevis, O. Krug, W. Schänzer Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry. J. Mass Spectrom. 2006, 41, 332.
11. R. Benesch, R. B. Benesch The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin. Biochem. Biophys. Res. Commun. 1967, 26, 162.
12. A. Arnone, M. F. Perutz Structure of inositol hexaphosphate-human deoxyhaemoglobin complex. Nature 1974, 249, 34.
13. W. N. Pollon, M. D. Robinson, B. C. Kim Deoxygenated sickle hemoglobin. Modulation of its solubility by 2, 3-diphosphoglycerate and other allosteric polyanions. J. Biol. Chem. 1985, 260, 13897.
14. K. C. Fylaktakidou, J. M. Lehn, R. Greferath, C. Nicolau Inositol tripyrophosphate: A new membrane permeant allosteric effector of haemoglobin. Bioorg. Med. Chem. Lett. 2005, 15, 1605.
15. C. D. Duarte, R. Greferath, C. Nicolau, J. M. Lehn myo-Inositol Trispyrophosphate: A novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane. Chem. Bio. Chem. 2010, 11, 2543.
16. T. Watanabe Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure. J. Am. Coll. Cardiol. 2008, 52, 779.
17. A. Biolo, R. Greferath, D. A. Siwik, F. Qin, E. Valsky, S. Pothukanuri, C. D. Duarte, R. P. Schwarz, J. M. Lehn, C. Nicolau, W. S. Colucci Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. Proc. Natl. Acad. Sci. 2009, 106, 1926.
18. NormOxys Inc. Clinical Development, CMC and Safety Of OXY111A. Available at: http://normoxys.com/clinical-trial-results/ [17 March 2014].
19. Standardbred Canada. Doctors discuss undetectable drugs. Available at: http://standardbredcanada.ca/news/11-4-10/doctors-discuss-undetectable-drugs.htmL [12 March 2014].
20. A. Cohen New drugs are here-what can be done? Available at: http://www.harnesslink.com/News/Cohen-New-drugs-are-here-what-can-be-done-83740 [12 March 2014].
21. HorsePreRace.com. ITPP products for horses. Available at: http://horseprerace.com/performance-supplements/blast-off-extreme-injection-30ml/ [17 March 2014].
22. A. S. Y. Wong, E. N. M. Ho, T. S. M. Wan Detection of myo-inositol trispyrophosphate in equine urine and plasma by hydrophillic interaction chromatography-tandem mass spectrometry. Drug Test. Anal. 2012, 4, 355.
23. ICH. Validation of analytical procedures: Text and methodology Q2(R1). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf [15 April 2014].
24. WADA. International standard for laboratories. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/ISL/WADA_Int_Standard_Laboratories_2012_EN.pdf [15 April 2014].
25. A. Alpert Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J. Chromatogr. 1990, 499, 177.
26. D. McCalley Study of the selectivity, retention mechanisms and performance of alternative silica-based stationary phases for separation of ionised solutes in hydrophilic interaction chromatography. J. Chromatogr. A 2010, 1217, 3408.
27. Macherey-Nagel. NUCLEODUR® HILIC and NUCLEOSHELL® HILIC - Useful complements to conventional C18 HPLC phases. Available at: http://www.mn-net.com/HPLCStart/NUCLEODURphases/NUCLEODURHILIC/ HILICBasics/tabid/ 11124/language/en-US/Default.aspx [12 March 2014].
28. N. Gray, J. Heaton, A. Musenga, D. A. Cowan, R. S. Plumb, N. W. Smith Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the quantification of ephedrines using medium-resolution accurate mass spectrometry. J. Chromatogr. A 2013, 1289, 37.
29. G. Lam, S. Zhao, J. Sandhu, R. Yi, D. Loganathan, B. Morrissey Detection of myo-inositol tris pyrophosphate (ITPP) in equine following an administration of ITPP. Drug Test. Anal. 2014, 6, 368.